Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

vvasnington,	D.C. 20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kelly Lisa				2	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET				3 0	3. Date of Earliest Transaction (Month/Day/Year) 07/14/2010							X Officer (give title Other (specify below) SVP, Human Resources						
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person								
		Tal	ole I - Non-	Derivati	ve Se	curities	s Ac	quired,	Dis	posed o	f, or Ber	neficial	y Owned					
Date						Date,	Code (Instr. 5)				5. Amour Securitie Beneficia Owned F	s For ally (D) ollowing (I) (Form (D) or	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Conversion or Exercise Price of Derivative Security (Instr. 3) 2. Conversion Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Code (Instr. 8) Se Ac (A) Dis		of Ex		5. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)		Date Exercisab		Expiration Date	Title	Amount or Number of Shares						
Stock	\$33.82	07/14/2010		A		30,500		10/14/201) (1)	07/13/2020	Common	30,500	\$ 0	30,500	0	D		

Explanation of Responses:

1. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010.

Remarks:

Valerie L. Andrews, Attorney-

07/16/2010

In-Fact
** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.